drugset / Trial / NCT00799448

Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes

NCT00799448

Phase 4 Terminated 40 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to compare the efficacy and safety of repaglinide combined with insulin NPH versus biphasic human insulin 30 alone in type 2 diabetics inadequately controlled with sulfonylurea (SU) +/ biguanide therapy

Timeline

Start
2003-09-16
Primary completion
2004-09-20
Completion
2004-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Repaglinide Small molecule
Subject biphasic human insulin 30 Unknown
Subject insulin NPH Protein / enzyme biologic